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Abstract: Cancer of the uterine cervix (CC) is the second most common cancer in women worldwide. In Colombia, CC is 
the second most frequent cancer among the entire women population and the first among women aged between 15 and 44 
years, with an estimated incidence of 24.9 cases/100,000 inhabitants. The main risk factor is infection with one or more 
high-risk human papillomavirus (HPV) types. The aim of this study was to estimate the genotype-specific prevalence of 
human papillomavirus (HPV) DNA in patients with cervical pathology using the multiplex PCR and Luminex xMAP 
technology. In addition, we compared genotyping with Luminex xMAP and with Reverse Line Blot (RLB). A cohort of 
160 patients participated in the study, of which 25.6% had no cervical lesions, 35% presented cervical intraepithelial 
neoplasia of grade I (CIN I), 10% CIN II, 20.6% CIN III and 8.8% CC. The most frequent viral types in all lesion grades 
were HPV16 and HPV18. Infections by a unique virus were less frequent (19.4%) than multiple infections (80.6%). 
Single infections were found in 22% of women with no cervical lesions, and in 14.3% of CIN I, 18.7% CIN II, 21.2% 
CIN III and 28.6% of CC. Multiple infections were observed in 78.0% of cervical samples with negative histopathologic 
diagnosis, and in 85.7% of CIN I, 81.2% CIN II, 78.8% CIN III and 71.4% CC. All samples analyzed with Luminex 
xMAP were HPV-positive, while we could detect HPV in only 48.8% of cases with RLB. Of the samples positive by both 
methods, there was a 67.2% correlation in the viral type(s) detected. In conclusion, Luminex suspension array showed a 
remarkably higher sensitivity compared with RLB. Multiple infections were unexpectedly common, being HPV types 16 
and 18 the most prevalent in all histopathologic grades. 
Keywords: Human papillomavirus (HPV), CIN, cervical cancer, reverse line blot (RLB), luminex xMAP, pap smear, abnormal 
cytology. 
INTRODUCTION  
  Cancer of the cervix (CC) is the second most common 
cancer in women worldwide, with estimated 500,000 new 
cases of CC per year. In developing countries CC remains as 
a major cause of morbidity and mortality in women [1, 2]. 
However, CC is a highly curable disease if detected at early 
stages [3, 4]. Early detection is effective because the 
precursor lesions develop slowly preceding invasive cancer, 
typically over a period greater than 10 years [5]. These 
precursor lesions, the so-called cervical intraepithelial 
neoplasia (CIN) grades I to III, are detectable by cervical 
cytology. In countries where cytology has been introduced, 
CC rates have declined substantially [5]. A subset of human 
Papillomavirus (HPV) types plays an essential role in CC 
development [6, 7]. Infection by oncogenic HPV types is 
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considered a prerequisite for the development of this 
neoplasm, and about 99% of cervical cancers are HPV-
infected [8, 9] although most infections are cleared by the 
immune system [5]. However, infection with HPV per se is 
not sufficient for cancer to develop, since a number of risk 
co-factors have been identified, such as early initiation of 
sexual intercourse, higher number of sexual partners, 
concurrent viral and bacterial infections, use of oral 
contraceptives, dietary habits, multiparity and smoking, 
among others [4, 10]. 
  Approximately 118 HPV types have been fully 
characterized to date. Of these, a subset infect the mucosa of 
the genital tract and have been divided into three groups: 1) 
high-risk (HR-HPV), including types 16, 18, the most 
prevalent in CC; 2) possibly high-risk (pHR-HPV); and 3) 
low-risk (LR-HPV) HPV [11]. 
  Because just high-risk HPVs are etiologically linked to 
CC, efforts have been made to improve the sensitivity of the 
methods for virus type detection in samples from women 
with abnormal genital cytology. HPV detection and typing HPV Prevalence in Colombian Women with Abnormal Cytology  The Open Virology Journal, 2011, Volume 5    71 
has become an essential tool for diagnostics and 
management of HPV-related disease. Molecular biology 
techniques, particularly PCR, made possible highly sensitive 
methods for detection of HPV DNA in cervical samples [12-
14]. HPV genotype can be determined analyzing the
  PCR 
products by hybridization with type-specific probes,
 
sequencing or restriction fragment length polymorphism. 
One of the most useful PCR methods for genotyping HPV 
has been nonradioactive reverse line blot (RLB), which uses 
the general primers GP5+/GP6+ (GP) to amplify the L1 
region of 37 mucosotropic HPV types [15]. The technique is 
based on hybridization of oligonucleotide probes specific for 
each viral type with biotinylated PCR products obtained 
from clinical specimens, which are detected with strepta-
vidin-peroxidase, revealed with enhanced chemilumini-
scence (ECL), and finally exposed to an autoradiography 
film. The RLB system has proven most useful for typing of
 
samples that were prescreened by HPV group-specific 
assays,
 such as HR-HPV or LR-HPV GP5+/6+ PCR-EIA or 
Hybrid Capture 2. 
  In recent years a multiplex HPV genotyping assay was 
developed based on GP PCR followed by subsequent 
detection of the biotinylated
 products with 22 type-specific 
oligonucleotide probes covalently
 coupled to distinct sets of 
fluorescently-labeled polystyrene
  beads [16]. (Luminex 
Technology). This method uses a broad spectrum 
BSGP5+/6+ (BS) primer set on
  the basis of mismatch 
reduction to 48 genital HPV types. In addition, the method 
incorporates -globin primers in the BS PCR as well
 as the 
standard GP PCR for internal DNA quality control. The 
sensitivity and performance of Luminex/BSGP5+/6+ was 
compared to that of standard RLB/GP5+/6+ with DNA 
extracted from cervical scrapings of a follow up population 
of 160 women with abnormal cervical cytology in Bogota, 
Colombia. 
MATERIALS AND METHODOLOGY 
Selection of Patients 
  We included in the study 160 adult women who were 
enrolled in a cervical cancer screening program
 and attending 
gynecologic services at different hospitals in the city of 
Bogota. Informed consent was signed by all participants, 
who voluntarily agreed taking part in the study for a period 
of eight months. Inclusion criteria were: women with history 
of borderline, mild or moderate dysplastic cytology (the 
criteria used for the cytologic diagnoses were those of The 
Bethesda System 2001) who were then referred to 
histopathology analysis, with the outcome of ‘normal’ or 
‘abnormal’, in which case the lesions were classified 
according to the CIN grading system by the pathologist. 
Exclusion criteria were: pregnancy, previous history of 
biopsy-confirmed CIN (any grade) or HPV infection, as well 
as having received antineoplastic therapy, immunotherapy or 
HPV vaccination. All participants included in the study 
underwent subsequent exploratory colposcopy with 
collection of cervical scraping smears and biopsy samples at 
the site where the abnormal lesion was localized for HPV 
genotyping and histopathology analysis, respectively. 
According to the outcome of such analysis, the patients were 
diagnosed following the CIN grading system (CIN grades I, 
II and III), CC or as “negative pathology”. The histo-
pathology findings were reviewed by a second pathologist, 
who was not blinded to the results. Those cases in which the 
diagnosis made by the two pathologists did not match were 
excluded from the study. 
Collection and Processing of Cervical Samples 
  The cervical scrapings were collected at at the lesion site 
by colposcopy using cyto-brushes, which were immediately 
placed in sterile tubes containing 1 ml of nucleic acid-free 
phosphate buffer saline (PBS) supplemented with 0.05% 
thimerosal. All samples were subsequently treated with 
proteinase K (Bioline
®) to a final concentration of 20 ug/ml, 
and incubated overnight at 37°C. Then, the proteinase K was 
inactivated at 95°C for 5 minutes, and the samples were 
centrifuged at 10.000 x g for 5 minutes and stored at -20°C 
until processed for DNA isolation. Cervical biopsies, taken 
at the site where the lesion was identified, were fixed with 
formalin and paraffin-embedded for histopathology analysis. 
DNA Isolation from Cervical Scrapings 
  DNA was isolated from the samples treated with 
proteinase K in the previous section by a two-step phenol 
extraction and one-step chloroform-isoamyl alcohol 
extraction followed by ethanol precipitation. DNA pellets 
were resuspended in 0.2 ml of 10
 mM Tris (pH 8.5) buffer 
and stored at -20°C until further
 analysis. 
Quality Assessment of DNA 
  Quality of DNA was confirmed by electrophoresis and 
by PCR with primers PC03/PC04, which amplify a 110 bp 
fragment of the ß-globin gene [17]. The reaction mixture 
contained 1X PCR buffer, 3.5 mM MgCI2, dNTP mix with 
200 M of each, PC03 and PC04 at 1 M each, 1.25 U of 
Taq polymerase (Promega
®) and distilled water to a total 
reaction volume of 25 L. The reactions were run on the My 
Cycler
TM Thermal Cycler (BioRad) using the following 
conditions: 4 minutes at 94 º C, followed by 40 cycles of 
amplification 94°C for 1 minute, 55ºC for 1 minute and 72ºC 
for 1 minute, and extension end at 72°C for 4 minutes. 
Lymphocyte DNA was used as positive control, and distilled 
water as negative control. The PCR products were visualized 
by gel electrophoresis on 1% agarose gels stained with 
ethidium bromide to identify the amplified 110pb band. The 
electrophoresis was run for one hour at 100 volts in TBE 
buffer using a BioRad Power PAC 3000 and visualized with 
a gel scanner with Quantity One software from BioRad. 
HPV Genotyping by RLB 
  For all samples positive for the ß-globin amplification, 
GP PCR was performed using the primers GP5+/5'-
biotinylated GP6+ as described elsewhere [15]. The reaction 
mixture contained 10 L of sample, 1X PCR buffer, 3.5 mM 
MgCI2, dNTPs mix (200 M of each deoxynucleoside 
triphosphate), GP5+ and 5'-biotinylated GP6+ primers at 1 
M each, 1.25 U of Taq polymerase (Promega
®) and sterile 
distilled water to a total reaction volume of 50 L. 
Amplification was carried out in a thermocycler MyCycler
TM 
(Biorad) and PCR conditions were: one step of denaturation 
at 94°C for 4 minutes, followed by 40 amplification cycles 
each with the following steps: denaturation at 94°C for 1 
minute, annealing at 40°C for 2 minutes and elongation at 
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by 4 minutes. As positive control we used DNA extracted 
from the cervical cancer cell lines HeLa and SiHa kindly 
provided by the laboratory of Pharmacogenetics from the 
National University of Colombia. 
  Detection was performed using an Immunetics 
Minibloter
® 45. This system uses membranes with carboxyl 
groups that are activated with 16% (w/v) EDAC (1-ethyl-3-(-
3-dimethylamininopropyl) carbodiimide) to covalently bind 
oligonucleotides coupled to amino groups, which detect 37 
types of HPV types as reported previously by Van den Brule 
[15]. Subsequently, the membrane is rotated 90 degrees, for 
hybridization with denatured PCR products at 42ºC for 45 
minutes, followed by two washes at 52 º C for 10 minutes 
with 2X SSPE (1X SSPE contains 0.18 M NaCl, 10 mM 
NaH2PO4 and 1 mM EDTA pH 7.4, Invitrogen) and 0.5% 
SDS. Then, the membrane was incubated with streptavidin-
peroxidase conjugate (Roche
®) (diluted 1:4000) for 45 
minutes at 42°C, followed by two washes in 2X SSPE and 
0.5% SDS for 10 minutes at 42 º C and two washes with 2X 
SSPE for 5 minutes at room temperature. Detection of 
specific hybridization was performed using ECL (GE 
Healthcare UK, Amersham) followed by exposure overnight 
of autoradiography film (Amersham Hyperfilm ™ ECL). 
The film was developed using a Medical Film Processor 
Model SRX-101 Konica Minolta Medical & Graphic, Inc. 
Multiplex HPV Genotyping (MPG) and Estimation of 
Viral Load 
  Multiplex BSGP5+/GP6+ PCR-MPG was carried out 
with primers reported previously by Schmitt et al., 2008 
[11]. The assay used nine sense primers BSGP5+ at 200 nM 
and 3 antisense primers 5'-biotinylated-BSGP6+ at 400 nM 
to amplify a ~150 bp fragment of the viral L1 ORF, as well 
as two additional primers (MS3/MS10) at 300 nM to amplify 
the ß-globin gene, which was used as DNA integrity control 
[18]. The multiplex Luminex hybridization assay enabled the 
detection of 27 mucosal HPV-genotypes: i) high risk (HR)-
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68; ii) possibly HR-HPV types: 26, 53, 67, 70, 73, 82; low 
risk (LR)-HPV types: 6, 11, 30, 43, 44 and 69. In addition, 
the -globin product was amplified in each sample. 
  Oligonucleotide probes with an amino group at the 5' end 
for each of the 27 HPV types were coupled to carboxylated 
beads using the carbodiimide procedure described by 
Schmitt et al., 2006 [16]. For each combination of probes 
and beads we used 2.5 million carboxylated beads in 25 L 
of 0.1 M2-(N-morpholino) ethanesulfonic acid (MES), pH 
4.5, with 200 g of N-(3-dimethylaminopropyl)-N-ethyl-
carbodiimide (EDC) and 400 pmol of probe, the mixture was 
incubated in the dark under stirring for 30 minutes, the 
addition of EDC and incubation was repeated once, then the 
beads were washed with 0.5 ml of 0.2 g/L of Tween 20 and 
once with 0.5 ml of 1.0 g/L SDS. Finally, they were stored at 
4 °C in TE solution. Hybridization was performed in 96 well 
plates with 10 L of PCR product in 33 L of hybridization 
solution (0.15 M of tetramethylammonium chloride (TMAC), 
75 mM Tris-HCl, 6 mM EDTA, 1.5 g/L Sarkosyl, pH 8.0) to 
which 2000 bead-coupled probes were added. This mixture 
was incubated at 95°C for 10 minutes and immediately 
placed on ice for 2 minutes, then it was placed at 41°C for 30 
minutes under stirring, then the samples were transferred to a 
wash plate with filter bottom (Millipore, Bedford, MA) pre-
equilibrated with blocking solution (PBS with 0.2 g/L 
Tween-20 and 2.0 M TMAC), and washed with blocking 
solution to eliminate non-hybridized DNA in a vacuum wash 
station (Millipore). Subsequently, biotinylated PCR products 
were stained with streptavidin-R-phycoerythrin
  conjugate 
(Molecular Probes) diluted 1:1600 in 2.0 M TMAC, 75 mM 
Tris-HCl, 6 mM EDTA, 1.5 g/L Sarkosyl, 1.0 g/L casein, pH 
8.0 and incubated 20 minutes at room temperature with 
shaking. After washing three times with blocking solution, 
the beads were analyzed in a Luminex 100 reader (Luminex 
Corp.), which uses two lasers, one that recognizes the bead 
set by the internal bead color and another to quantify
  the 
reporter fluorescence on the bead. The results were 
expressed in median fluorescence intensities (MIF) of 100 
beads per sample [11, 16, 18, 19]. 
  As control, plasmid standards from the WHO panel II 
[20] with 100 and 1,000 copies for 16 distinct HPV types per 
100ng human placental DNA were amplified and served to 
estimate the HPV viral load. MFI values obtained with 1,000 
HPV genome copies of the respective HPV types per 100 ng 
of human placental DNA served as cutoff for defining low 
(<cutoff) and high viral load (>cutoff) groups. 
Statistical analysis 
  The demographic data was analyzed using Statistix 9 
software. The genotyping results were analyzed using 
Excel
®. For each probe, MFI values in reactions with no PCR 
product
  added to the hybridization mixture were considered 
background
 values. Reactions with net MFI values above 5 were 
defined
 as positive reactions. Net MFI values were computed by 
subtraction of 1.1 times
 the median background value. For all 
probes, this cutoff value
 was above the mean background plus 
three times the standard
  deviation..  P values of <0.05 were 
considered statistically
 significant. 
RESULTS 
Population Under Study 
  Inclusion and exclusion criteria for selection of the study 
population are defined in the Methods section. All 
participants had a history of abnormal cervical cytology 
(atypical squamous cells, any grade, according to The Bethesda 
System 2001) and underwent subsequent colposcopy and 
histopathology analysis, which led to their classification into 
one of the five groups: negative pathology, CIN I, CIN II, 
CIN III and CC. The Table 1 resumes the socio-demographic 
and anamnestic characteristics of the study population 
distributed by the grade of the lesions found in the 
histopathologic analysis. Nearly 51% of the participants in 
the study were under the age of 34 years, with ~52% 
belonging to socioeconomic levels 1 or 2, classified 
according to the criteria of the Secretary for District 
Planning and the National Administration Department for 
Statistics (DANE, Decreto 304, 2008). Nearly half of the 
population (50.6%) had their first sexual intercourse under 
the age of 18, and about 70% had 1-2 sexual partners. The 
majority of women participating in the study had children 
(85.6%), and their first delivery was in most cases (87.6%) 
previous to the age of 24. A large number (56.9%) never 
used contraceptive methods. About 63% had no family 
history of cancer. A family history of CC was infrequent in 
all types of CIN lesions (Table 1) and even absent in the CC  
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patients. However, a family history of other types of cancer 
was found in a significant number of women in all groups 
with a maximum in CIN II (43.8%). 
 
Histopathologic Characteristics 
  The distribution of cervical cancer and its precursor 
lesions among the study population is summarized in Table 
2. Of the 160 study participants 41 (25.6%) did not show any 
Table 1.  Characteristics of the Study Population 
 
Histopathologic Diagnosis (1) 
Characteristic  Negative 
Pathology 
n (%) 
CIN I 
n (%) 
CIN II 
n (%) 
CIN III 
n (%) 
CC 
n (%) 
Total 
n (%) 
(2) 
Age (Years) 
< 25 
25-44 
45-64 
>65 
 
10  (24.4) 
21 (51.2) 
10 (24.4) 
0 (0) 
 
20 (35.7) 
28 (50.0) 
8 (14.3) 
0 (0) 
 
4 (25.0) 
10 (62.5) 
2 (12.5) 
0 (0) 
 
2 (6.1) 
19 (57.5) 
12 (36.4) 
0 (0) 
 
2 (14.3) 
2 (14.3) 
9 (64.3) 
1 (7.1) 
 
38 (23.7) 
80 (50.0) 
41 (25.7) 
1 (0.6) 
Socioeconomic level (3) 
Low 
Medium 
High 
 
21 (51.2) 
18 (43.9) 
2 (4.9) 
 
29 (51.8) 
22 (39.3) 
5 (8.9) 
 
9 (56.3) 
4 (25) 
3 (18.8) 
 
17 (51.5) 
15 (45.5) 
1 (3.0) 
 
7 (50) 
7 (50) 
0 (0) 
 
83 (51.9) 
66 (41.2) 
11 (6.9) 
Age of first intercourse (years) 
< 18 
18 - 24 
25 - 32 
 
20 (48.8) 
20 (48.8) 
1 (2.4) 
 
30 (53.6) 
25  (44.6) 
1 (1.8) 
 
10 (62.5) 
6 (37.5) 
0 (0) 
 
13 (39.4) 
20 (60.6) 
0  (0) 
 
8 (57.1) 
6 (42.9) 
0 (0) 
 
81 (50.6) 
77 (48.1) 
2 (1.3) 
No. of sexual partners 
1 - 2 
3 - 4 
5 - 6 
7 + 
 
27 (65.9) 
11 (26.8) 
2 (4.9) 
1 (2.4) 
 
36 (64.3) 
14 (25.0) 
4 (7.1) 
2 (3.6) 
 
9 (56.3) 
5 (31.3) 
2 (12.5) 
0 (0) 
 
25 (75.8) 
4 (12.1) 
3 (9.1) 
1 (3.0) 
 
10 (71.4) 
4 (28.6) 
0 (0) 
0 (0) 
 
107 (66.9) 
38 (23.7) 
11 (6.9) 
4 (2.5) 
Age at 1st delivery 
< 18 
18 - 24 
25 - 32 
33 + 
 
10 (27.8) 
23 (63.9) 
3 (8.3) 
0 (0) 
 
7 (15.2) 
30 (65.2) 
7 (15.2) 
2 (4.4) 
 
3 (25) 
9 (75) 
0 (0) 
0 (0) 
 
6 (20.7) 
18 (62.1) 
5 (17.2) 
0 (0) 
 
4 (28.6) 
10 (71.4) 
0 (0) 
0 (0) 
 
30 (18.7) 
90 (56.3) 
15 (9.4) 
2 (1.3) 
No. of Pregnancies 
0 
1-2 
3-4 
5+ 
 
5 (12.2) 
24 (58.5) 
10 (24.4) 
2 (4.9) 
 
10 (17.9) 
34 (60.7) 
11 (19.6) 
1 (1.79) 
 
4 (25.0) 
7 (43.8) 
5 (31.3) 
0 (0) 
 
4 (12.1) 
13 (39.4) 
13 (39.4) 
3 (9.1) 
 
0 (0) 
6  (42.9) 
1 (7.1) 
7 (50.0) 
 
23 (14.4) 
84 (52.5) 
40 (25) 
13 (8.1) 
Contraceptives (any method) 
Yes 
No 
 
14 (34.1) 
27 (65.9) 
 
27 (48.2) 
29 (51.8) 
 
11 (68.8) 
5 (31.3) 
 
12 (36.4) 
21 (63.6) 
 
5 (35.7) 
9 (64.3) 
 
69 (43.1) 
91 (56.9) 
History of STD 
Yes 
No 
 
2 (4.88) 
39 (95.1) 
 
4 (7.14) 
52 (92.9) 
 
1 (6.2) 
15 (93.8) 
 
0 (0) 
33 (100) 
 
0 (0) 
14 (100) 
 
7 (4.4) 
153 (95.6) 
History of vaginal Infections 
Yes 
No 
 
4 (9.8) 
37 (90.2) 
 
9 (16.1) 
47 (83.9) 
 
2 (12.5) 
14 (87.5) 
 
10 (30.3) 
23 (69.7) 
 
5 (35.7) 
9 (64.3) 
 
30 (18.7) 
130 (81.3) 
Family history of cancer 
Cancer (general) 
Cervical cancer 
None 
 
11 (26.8) 
3 (7.3) 
27 (65.9) 
 
15 (26.8) 
2 (3.6) 
39 (69.6) 
 
7 (43.8) 
1 (6.2) 
8 (50) 
 
12 (36.4) 
3 (9.1) 
18 (54.5) 
 
5 (35.7) 
0 (0) 
9  (64.3) 
 
50 (31.2) 
9 (5.7) 
101(63.1) 
(1) Percentages relative to the total number of cases in each group (see Table 2). 
(2) Percentages relative to the total number of participants in the study. 
(3) According to the criteria of the Colombian the Secretary for District Planning and the National Administrative Department of Statistics (DANE, Decreto 304, 2008). 74    The Open Virology Journal, 2011, Volume 5  García et al. 
detectable cervical lesions in the histopathology analysis. 
The remainder 119 cases were diagnosed of cervical lesions 
at different stages: 56 (35%) with low-grade cervical lesions 
(CIN I), 49 (30.6%) with high-grade cervical lesions (CIN II 
and CIN III) and 14 women (8.8%) were diagnosed of CC 
(either in situ or invasive carcinoma). 
  In a previous study, Wright and colleagues estimated the 
sensitivity of the cytology screening to be about 60.7% [21], 
with a trend to increase with higher degree of dysplasia. In 
our study, the sensitivity of the Pap smear was determined to 
be 69,6% for CIN I, 40% for CIN II, 63% for CIN III and 
78,6% for CC. 
HPV Prevalence 
  The majority of CIN and CC cases are linked to infection 
by the so-called high-risk HPVs, a subset of oncogenic HPV 
types with mucosal tropism [6, 7]. We used both multiplex 
PCR and Luminex xMAP technology as well as reverse line 
blot (RLB) analysis for detection and genotyping of the HPV 
types 16 and 18, the most prevalent in CC, in DNA isolated 
from cervical smears of all the patients participating in the 
study. As expected, these two viral types were found at high 
frequencies in all five histopathologic groups. With the 
Luminex xMAP technique HPV16 and HPV18 were 
detected in separate or combined infections in 80.5% of 
women with negative histopathology diagnosis, 83.9% of 
low-grade lesions (CIN I), 91.8% of high-grade lesions (CIN 
II and CIN III) and 100% of CC (Table 2, middle column). 
In contrast, the RLB analysis detected the presence of these 
virus types at markedly lower frequencies in all groups 
(Table 2, right column), suggesting that, in our hands, this 
technique is less sensitive than the Luminex xMAP method. 
Furthermore, in those samples positive for HPV by both 
methods there was a 67.2% coincidence in the HPV type(s) 
detected (p<0.05). Therefore, Luminex xMAP was chosen to 
detect up to 27 mucosotropic HPV types in cervical 
scrapings of all the women included in the study. Table 3 
summarizes the prevalence of the HPV types that were 
detected in the five histopathologic groups of our study 
population. 
  Using Luminex xMAP one or more HPV types were 
demonstrated in the cervical smears of all 160 participants in 
the study. Table 3 shows the 27 HPV types that were 
detected. Of these, 16 were high-risk (HR), 2 possibly high-
risk (pHR) and 9 low-risk types commonly found in genital 
warts and low-grade cervical lesions [22]. The data in Table 
3 reflects the HPV types detected either as unique or 
double/multiple infections. HPV16 was by far the most 
prevalent virus (overall prevalence 84.4%), ranging from 
75.6% in the negative pathology group to 100 in CC. The 
second most common virus type was HPV18 (overall 
prevalence 84.4%), with 53.6% in the negative pathology 
group and over 60% in all CIN groups, the lowest prevalence 
being in the CC group (28.5%). Among the remainder HR-
HPV types, only five were found in CC: HPV45, 52, 56, 68 
and 69, although all HR-HPV types detected in our study 
were also present in the negative pathology and/or the CIN 
groups. Of the two pHR-HPV types detected (HPV53 and 
66) only HPV53 was found in CC, albeit HPV66 was present 
in all other groups with a relatively high prevalence (about 
10-15%). Among the LR-HPV types only four types were 
found in CC (HPV6, 42, 69 and 70) of which HPV6 showed 
the highest prevalence (21.4%). 
  The accuracy of the Luminex genotyping was further 
confirmed by analyzing the expression of early genes (E6 
and E7) of the most prevalent HR-HPVs detected with this 
technique (HPV types 16, 18, 31, 33, 45, 51, 52, 56 and 58). 
To this end, we isolated total RNA from biopsy material of 
the patients positive for these virus types and, after reverse 
transcription and DNase I treatment, analyzed them by 
quantitative real time PCR (QRT-PCR) using specific 
primers for E7 or E6/E7 transcripts. The results validated 
those obtained with Luminex, since all samples identified as 
positive for the specific virus types by Luminex amplified 
their respective transcripts by QRT-PCR (data not shown). 
Single Versus Multiple Infections 
 The  Table  4 shows the frequencies of infection with HR, 
pHR and LR-HPVs found in the five histopathologic groups 
as single or multiple events. Overall, the frequency of 
multiple infections (129/160 cases, 80.6%) was about 4-fold 
higher than that of single infections (31/160, 19.4%), a trend 
that was conserved in the five groups of patients. HR-HPV 
types were the most prevalent in all cases of infection with a 
unique virus, the highest prevalence being in the CC group 
(28.6%). In contrast, single infections with LR-HPVs were 
rare and were not observed at stages above CIN II. There 
was just one case of single infection by pHR-HPV in the 
negative pathology group. In the samples infected with more 
than one HPV type, the combination of two or more HR-
HPVs was the most frequent (70/160, 43.7%), followed by 
HR+LR infections (43/160, 26.9%). The combination of 
HR+pHR was rare (16/160, 10%) (Table 4). Within the CC 
Table 2.  Histopathologic Diagnosis and Incident Rates of HPV Types 16 and 18 in the Study Population 
 
Diagnosis  No. Cases 
n (%) 
HPV 16 and/or 18 Prevalence with Luminex (%) (a)  HPV 16 and/or 18 Prevalence with RLB (%) (b) 
Negative pathology   41 (25.6)  80.5 33.3 
Low-grade cervical lesions (c)  56 (35)  83.9  43.4 
High-grade cervical lesions (d)  49  (30.6)  91.8 67.5 
Cervical cancer  14  (8.8)  100  66.6 
Total  160  (100)  - - 
(a) HPV genotyping with Luminex xMAP technology as described in Materials and Methods. 
(b) HPV genotyping with RLB as described in Materials and Methods. 
(c) Low grade cervical lesions: CIN I. 
(d) High grade cervical lesions: CIN II, CIN III. HPV Prevalence in Colombian Women with Abnormal Cytology  The Open Virology Journal, 2011, Volume 5    75 
group, HR+LR-HPV infections were more frequent (5/14, 
35.7%) than infections with multiple HR-HPV types (4/14, 
28.6%). However, such differences were not statistically 
significant (p>0.1, one way ANOVA). 
HPV Prevalence by Age 
  Analysis of the prevalence of HR-HPVs by age showed 
an overwhelming presence of these viruses in all age groups, 
with over 97% of women above the age of 25 being positive 
(Table 5). Among the HR-HPVs, HPV16 and 18 were found 
in 80-90% of cases, as single or multiple infections. The LR-
HPVs showed much lower frequency rates, with a maximum 
in the group less than 25 years old (42.1%). Likewise, pHR-
HPVs had their maximal prevalence in the same age group, 
but with a lower frequency rate (23.7%). 
Viral Load 
  The viral load was estimated in the DNA isolated from 
the cervical scrapings by calculating the HPV copy number 
against standards. As can be appreciated in the Table 6, the 
samples infected with HR-HPVs, especially HPV types 16, 
18, but also types 31, 33, 52 and 58, had an overall tendency 
towards a stronger viral load, which correlated with the 
degree of dysplasia. However the differences seen were not 
statistically significant. For the two most prevalent HR-HPV 
types, 16 and 18, the highest copy numbers were found in 
the group diagnosed of CIN II in which about 80% had more 
than 50 viral copies. Interestingly, the viral load of these two 
Table 3.  Prevalence of High-Risk (HR), Putative High-Risk (pHR) and Low-Risk (LR) HPV Types in Cervical Smears Taken from 
Women with Negative Histopathologic Diagnosis and in Patients with CIN and CC 
 
HPV Type (*)  Negative Pathology 
n (%) (**) 
CIN I  
n (%) (**) 
CIN II  
n (%) (**) 
CIN III  
n (%) (**) 
Cervical Cancer 
n (%) (**) 
Total by HPV Type 
n (%) (**) 
Total by HPV Risk Group 
n (%) (***) 
16  31  (75.6)  45  (80.3)  14  (87.5)  31  (93.9)  14  (100)  135  (84.4) 
18  22  (53.6)  39  (69.6)  10  (62.5)  22  (66.6)  4  (28.5)  97  (60.6) 
31  1  (2.4)  2  (3.6)  2  (12.5)  2  (6)  0  (0)  7  (4.4%) 
33  1  (2.4)  3  (5.3)  0  (0)  3  (9)  0  (0)  7  (4.4%) 
35  3  (7.3)  4  (7.1)  0  (0)  1  (3)  0  (0)  8  (5%) 
39  6  (14.6)  2  (3.6)  0  (0)  4  (12.1)  0  (0)  12  (7.5%) 
45  2  (4.9)  5  (8.9)  3  (18.7)  2  (6)  1  (7.1)  13  (8.1%) 
51  5  (12.2)  7  (12.5)  1  (6.2)  1  (3)  0  (0)  14  (8.7%) 
52  3  (7.3)  6  (10.7)  2  (12.5)  4  (12.1)  2  (14.3)  17  (10.6%) 
56  9  (22)  15  (26.7)  2  (12.5)  0  (0)  1  (7.1)  27  (16.9) 
58  1  (2.4)  7  (12.5)  1  (6.2)  2  (6)  2  (14.3)  13  (8.1%) 
59  0  (0)  2  (3.6)  0  (0)  1  (3)  1  (7.1)  4  (2.5%) 
68a  2  (4.9)  2  (3.6)  0  (0)  0  (0)  0  (0)  4  (2.5%) 
68b  0  (0)  3  (5.3)  0  (0)  3  (9)  0  (0)  6  (3.7%) 
73  0  (0)  0  (0)  1  (6.2)  2  (6)  0  (0)  3  (1.9%) 
HR 
82  2  (4.9)  3  (5.3)  0  (0)  0  (0)  0  (0)  5  (3.1%) 
154 (96.25%) 
53  2  (4.9)  2  (3.6)  0  (0)  3  (9)  1  (7.1)  8  (5%) 
pHR 
66  4  (9.7)  6  (10.7)  2  (12.5)  5  (15.1)  0  (0)  17  (10.6%) 
22 (13.75%) 
6  2  (4.9)  1  (1.8)  3  (18.7)  0  (0)  3  (21.4)  9  (5.6%) 
11  0  (0)  2  (3.6)  2  (12.5)  1  (3)  0  (0)  5  (3.1%) 
30  2  (4.9)  3  (5.3)  1  (6.2)  1  (3)  0  (0)  7  (4.4%) 
42  0  (0)  5  (8.9)  1  (6.2)  2  (6)  1  (7.1)  9  (5.6%) 
43  2  (4.9)  1  (1.8)  0  (0)  0  (0)  0  (0)  3  (1.9%) 
44  0  (0)  4  (7.1)  0  (0)  0  (0)  0  (0)  4  (2.5%) 
67  1  (2.4)  1  (1.8)  0  (0)  1  (3)  0  (0)  3  (1.9%) 
69  1  (2.4)  0  (0)  2  (12.5)  1  (3)  1  (7.1)  5  (3.1%) 
LR 
70  2  (4.9)  4  (7.1)  0  (0)  1  (3)  1  (7.1)  8  (5%) 
50 (31.25%) 
(*) A total of 28 HPV types were tested of which the 27 types shown could be detected either as unique or combined double/multiple infections. The pHR-HPV type 26, which was 
also tested, resulted negative in all samples analyzed. 
(**) Percentages relative to the total number of cases in each group. 
(***) Percentages relative to the total number of participants in the study. 76    The Open Virology Journal, 2011, Volume 5  García et al. 
viruses decreased in CIN III and CC (p<0.05). In contrast, 
most samples infected with LR-HPVs contained less than 50 
viral copies, with the exception of those infected with HPV6, 
a significant number of which carried higher numbers of 
copies, particularly in CIN I and II lesions (p<0.05). Of the 
two pHR-HPVs that were detected, HPV53 was in the range 
below 50 copies, while HPV66 showed a tendency to higher 
viral load, largely in the CIN I group, but the difference was 
not statistically significant. 
Table 5.  Prevalence by Age of HR, pHR and LR HPV Types 
(Single and Multiple Infections) 
 
Age  HR 
n (%) 
pHR 
n (%) 
LR 
n (%) 
HPV 16 and/or 18 
n (%) 
< 25  35 (92.1)  9 (23.7)  16 (42.1)  31 (81.6) 
25-44  78 (97.5)  10 (12.5)  22 (27.5)  69 (86.2) 
45-64  40 (97.6)  4 (9.7)  12 (29.3)  37 (90.2) 
> 64  1 (100)  0 (0)  0 (0)  1 (100) 
The prevalence of HPV16 and 18 is denoted separately in the right column. 
Percentages are relative to the total number of cases in each group (see Tables 1 and 2). 
 
DISCUSSION 
  In this multicenter study we analyzed the prevalence of a 
subset of genital HPVs in 160 patients with abnormal 
cervical cytology, who were subsequently examined and 
diagnosed by the pathologists and classified into five groups 
ranging from absence of appreciable pathology to cervical 
cancer. These women agreed to participate in our study and 
donated a part of the cervical scrapings taken for diagnostic 
purposes to be used for HPV detection and typification. It 
has been estimated that 99.7% of invasive CC cases 
worldwide are associated with infection by HPV [8]. The 
HPV types with genital tropism have been divided into three 
groups: HR, pHR and LR. Infection with HR-HPV types is 
an essential risk factor for progression of cervical dysplastic 
lesions to CC. Hence, HPV detection and typification has 
become a routine tool in cervical screening, epidemiological 
studies, as well as for monitoring CIN and CC progression. 
HPV detection provides diagnostic and prognostic value, 
which should improve the relatively low sensitivity of 
cytology, estimated to be about 60.7% [Ref. 21 and our own 
results]. 
  A first aim of our study was to compare the sensitivity of 
two methods of HPV detection: RLB, a quick and easy 
method designed to identify HPV genotypes [15], and 
Luminex xMAP, a highly sensitive automated technique 
developed recently [11], which can detect 27 HPV types 
simultaneously. Our results show that the sensitivity of 
Luminex xMAP for HPV detection is remarkably higher 
than that of RLB (see Table 2). This was shown for HPV16 
and 18, which are the most prevalent viruses found in CC, 
but was also confirmed for other HPV types with lower 
prevalence (data not shown). Overall, the frequency of 
detection with Luminex xMAP of these two viral types in the 
negative pathology and low-grade groups was significantly 
higher than with RLB (2.4-fold and 1.9-fold, respectively), 
and was also higher in the high-grade and CC groups (about 
1.4-fold). The lower sensitivity of RLB cannot be explained 
by differences in the quality of the samples, which were the 
same for both RLB and Luminex, but may reflect the higher 
sensitivity of the probes used and the assay as has been 
reported previously (16). 
  The application of Luminex xMAP technology to the 
detection of HR, pHR and LR-HPV types in cervical 
scrapings of our study population showed a considerable 
prevalence of HR-HPV (96.25%), comparable to that 
reported previously [22, 23] (Table 3). Overall, the most 
prevalent viral types were HPV16 (84.4%) and HPV18 
(60.6%), followed by HPV56 (16.9%), HPV52 and 66 (both 
10.6%). These values are higher than those reported 
previously by Clifford et al. in cytologically normal women 
[24]. Such discrepancy may be explained by the fact that our 
study population was selected among women with a history 
of abnormal cytology and thus more likely to harbor HPV 
infections. Surprisingly, the high prevalence of HPV18 in 
CIN I, II and III, which was over 60%, dropped to 28.5% in 
CC. Other HR-HPVs (types 31, 33, 35, 39, 51, 68a, 68b, 72 
and 88), which had a significant prevalence in CIN lesions, 
were absent in CC. The same was observed for the pHR-
HPV type 66. This phenomenon suggests that these HPV 
types may act as companions/helpers of more prevalent 
HPVs during the precancerous CIN stages, but cannot 
overcome the oncogenic capability of the later, in particular 
Table  4.  Frequencies of HR, pHR and LR-HPV Single and Multiple Infections Among the Different Histopathologic Groups 
within the Study Population 
 
Single Infections  Multiple Infections 
Histopathologic Diagnosis 
HR pHR  LR Total 
n (%)  HR + LR  HR + pHR  HR  Total 
n (%) 
Neg. Pathology n (%) (*)  7 (17.1)  1 (2.4)  1 (2.4)  9 (22.0)  9 (22.0)  5 (12.2)  18 (46.3)  32 (78.0) 
CIN I n (%) (*)  6 (10.7)  0 (0.0)  2 (3.6)  8 (14.3)  17 (30.4)  5 (8.9)  26 (46.4)  48 (85.7) 
CIN II n (%) (*)  2 (12.5)  0 (0.0)  1 (6.2)  3 (18.7)  5 (31.2)  2 (12.5)  6 (37.5)  13 (81.2) 
CIN III n (%) (*)  7 (21.2)  0 (0.0)  0 (0.0)  7 (21.2)  7 (21.2)  3 (9.1)  16 (48.5)  26 (78.8) 
CC n (%) (*)  4 (28.6)  0 (0.0)  0 (0.0)  4 (28.6)  5 (35.7)  1 (7.1)  4 (28.6)  10 (71.4) 
Total n (%) (**)  26  (16.3)  1 (0.6)  4 (2.5)  31 (19.4)  43 (26.9)  16 (10)  70 (43.7)  129 (80.6) 
(*) Percentages relative to the total number of patients in each histopathologic group. 
(**) Percentages relative to the total number of patients participating in the study. HPV Prevalence in Colombian Women with Abnormal Cytology  The Open Virology Journal, 2011, Volume 5    77 
HPV16, are less prone to integrate in the host genome and 
disappear. It is noteworthy that also LR-HPVs were detected 
in advanced CIN lesions, though only four types (HPV 6, 42, 
69 and 70) were found in CC, of which HPV6 was the most 
prevalent (~20%). 
  A majority of the participants in the study (~80%) were 
positive for several HPV types (Table 4), indicating that 
multiple infections are a common phenomenon. Indeed, 
multiple infections have been detected with the Luminex 
technique in up to 58% of DNA samples from cervical 
scrapings of women participating in a population-based 
cervical screening trial in Mongolia [25]. A recent study in a 
Colombian population found 62.5% of multiple infections 
among HPV-infected women by conventional PCR [26]. The 
higher frequency of multiple infections found in our study as 
compared to this may reflect the higher sensitivity of the 
Luminex assay. 
  Multiple infections with only HR-HPV types were the 
most frequent, followed by the combination of HR and LR-
HPV and of HR with pHR-HPV types. Interestingly, in the 
CC group HR+LR-HPV infections were slightly more 
frequent (35.7%) than infections with HR-HPV types 
(28.6%), the most prevalent being HPV6. This result 
suggests that the LR-HPVs persist in cancer lesions possibly 
as commensals, since all CIN III were negative for HPV6. A 
larger cohort of patients should be analyzed to confirm such 
high frequency of non-oncogenic LR-HPVs in CC. As could 
be expected, in those CIN III and CC cases in which a 
unique HPV type was detected this was a HR-HPV. Our 
results are in contrast with those of Muñoz and colleagues, 
Table 6.  Viral Load Values Arranged into Three Groups (<50, 50-500 and >500 Copies), Determined by PCR in the Cervical 
Smears of the Study Population Distributed by Histopathologic Diagnosis 
 
Negative Pathology  CIN I  CIN II  CIN III  CC 
HPV Risk Group  HPV Type 
< 50  50 - 500  > 500  < 50  50 - 500  > 500  < 50  50 - 500  > 500  < 50  50 - 500  > 500  < 50  50 - 500  > 500 
16 77.4*  19,4*  3,2  61,7*  31,9*  6,4  21,4*  64,3*  14,3*  48,4  45,2  6,4  58,3  41,7*  0 
18 68,2  31.8*  0  51,2  48,8  0  20  80*  0  30,4  69,6*  0  66,7  33,3*  0 
31 0  0  100  0  0  100  50  0  50  0  0  100  0  0  0 
33 0  0  100  33,3  66,7  0  0  0  0  0  50  50  0  0  0 
35 50  0  50  100  0  0  0  0  0  0  0  100  0  0  0 
39 0  16,7  83,3*  50  0  50  0  0  0  75  25  0  0  0  0 
45 100  0  0  100  0  0  66,6  0  33,4  100  0  0  100  0  0 
51 60  0  40  71,4  0  28,6  0  100  0  0  100  0  0  0  0 
52 100  0  0  50  50  0  100  0  0  33,4  66,6  0  50  50  0 
56 77,8  22,2  0  80  20  0  100  0  0  0  0  0  100  0  0 
58 100  0  0  28,6  42,8  28,6  0  0  100  0  50  50  0  0  0 
59 0  0  0  0  100  0  0  0  0  100  0  0  0  0  0 
68a 100  0  0  100  0  0  0  0  0  0  0  0  0  0  0 
68b 0  0  0  100  0  0  0  0  0  100  0  0  0  0  0 
73 0  0  0  0  0  0  100  0  0  100  0  0  0  0  0 
HR-HPV 
82 100  0  0  100  0  0  0  0  0  0  0  0  0  0  0 
53 100  0  0  100  0  0  0  0  0  100  0  0  ND  0  0 
pHR-HPV 
66 74,9  0  25,1  50  33,3  16,7  100  0  0  80  0  20  0  0  0 
6 50  50  0  0  0  100  33,4  0  66,6*  0  0  0  66,7  33,3  0 
11 0  0  0  100  0  0  100  0  0  100  0  0  0  0  0 
30 100  0  0  100  0  0  100  0  0  0  0  0  0  0  0 
42 0  0  0  100  0  0  100  0  0  100  0  0  0  0  0 
43 100  0  0  100  0  0  0  0  0  0  0  0  0  0  0 
44 0  0  0  100  0  0  0  0  0  0  0  0  0  0  0 
67 100  0  0  100  0  0  0  0  0  100  0  0  ND  0  0 
69 100  0  0  0  0  0  100  0  0  100  0  0  ND  0  0 
LR-HPV 
70 100  0  0  100  0  0  0  0  0  100  0  0  100  0  0 
Values are percentages relative to the total number of positive cases for each HPV type in the corresponding histopathologic group. ND: not determined. 
(*) Values were statistically significantly different. 78    The Open Virology Journal, 2011, Volume 5  García et al. 
who reported frequencies of 91.9% and 8.1% for single and 
multiple infections, respectively [22]. In that study, HPV 
detection and typing was made by a PCR assay using 
MY09/MY11 and GP5+/6+ primers. Therefore, the 
discrepancy can be explained by the different sensitivity of 
the techniques used in both studies. 
  The distribution of infections with the different HPV 
types by age showed a remarkably high prevalence of HR-
HPVs in all age groups. HPV types 16 and 18 were the most 
prevalent, even in younger women. These results are in 
support of vaccination against those viruses as early as 
possible. 
  The viral load data showed a trend of HR-HPVs towards 
higher copy numbers correlating with the degree of 
dysplasia. For lesions infected with HPV16 and 18, of which 
a larger number of cases was analyzed, CIN II appeared to 
be the lesion with higher viral load. A possible explanation 
for this may be the episomal state of the virus at that stage, 
which may allow for accumulation of higher numbers of 
copies, what may not happen after the virus integrates into 
the host genome at later stages. Viral load of LR-HPVs was 
in the lower range, except for HPV6, which showed a 
tendency to higher copy numbers in CIN lesions. 
  Altogether, these results indicate that HPV16 may play a 
more essential role in the development of CC in Colombian 
women than previously thought. The frequency of HPV16 
was previously reported to be nearly 50% in HPV-positive 
women in Colombia [26]. In contrast, in our study 
population we found a significantly higher frequency of 
HPV16 (84.4%). Again, the higher sensitivity of our 
Luminex assay compared to the standard PCR used in that 
study may account for the difference, although geographical 
and socioeconomic factors related with the two populations 
might have also contributed to the higher HPV16 frequency 
observed in ours. 
  Furthermore, since HPV16, the most oncogenic HPV 
known, was detected in all CC cases, the presence of other 
HPV types in the same lesions may represent concomitant 
infections. It remains to be determined to which extent each 
virus contributes to the oncogenic transformation. Further, it 
needs to be clarified whether these co-infections occur in the 
same or in different cervical epithelial cells needs to be 
clarified, for instance by in situ hybridization analysis of 
biopsy samples using type-specific probes. 
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ABBREVIATIONS 
CC  =  Cancer of the uterine cervix 
CIN  =  Cervical intraepithelial neoplasia 
HPV =  Human  papillomavirus 
pHR  =  Possibly high risk 
HR =  High  risk 
LR =  Low  risk 
MFI =  Mean  fluorescence  intensity 
RLB  =  Reverse line blot 
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